Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

BACKGROUND: Glioblastoma (GB) is incurable at present without established treatment options for recurrent disease. In this phase I first-in-human clinical trial we investigated safety and feasibility of adoptive transfer of clonal chimeric antigen receptor (CAR)-NK cells (NK-92/5.28.z) targeting HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Michael C, Forster, Marie-Therese, Romanski, Annette, Straßheimer, Florian, Macas, Jadranka, Zeiner, Pia S, Steidl, Eike, Herkt, Stefanie, Weber, Katharina J, Schupp, Jonathan, Lun, Jennifer H, Strecker, Maja I, Wlotzka, Karolin, Cakmak, Pinar, Opitz, Corinna, George, Rosemol, Mildenberger, Iris C, Nowakowska, Paulina, Zhang, Congcong, Röder, Jasmin, Müller, Elvira, Ihrig, Kristina, Langen, Karl-Josef, Rieger, Michael A, Herrmann, Eva, Bonig, Halvard, Harter, Patrick N, Reiss, Yvonne, Hattingen, Elke, Rödel, Franz, Plate, Karl H, Tonn, Torsten, Senft, Christian, Steinbach, Joachim P, Wels, Winfried S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628939/
https://www.ncbi.nlm.nih.gov/pubmed/37148198
http://dx.doi.org/10.1093/neuonc/noad087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628939/
https://www.ncbi.nlm.nih.gov/pubmed/37148198
http://dx.doi.org/10.1093/neuonc/noad087

Ejemplares similares